Pharmanovia acquires a global portfolio of products for the central nervous system (CNS) from Sanofi

- Pharmanovia acquires 11 CNS brands, including Frisium® (clobazam) and Gardenal® (phenobarbital) - The portfolio is available in more than 60 mar...

September 19, 2023 | Tuesday | News
argenx Receives Favorable CHMP Opinion for Subcutaneous Efgartigimod in Myasthenia Gravis

Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigim...

September 15, 2023 | Friday | News
Eurofins Genomics Adopts Olink® Tech for Precision Medicine Advancement

Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the collaboration with Eurofins Genomics to bolster its offerings in the fields...

September 13, 2023 | Wednesday | News
Herophilus Announces Strategic Transaction with Genentech for Next-Generation Drug Discovery Platform

“Since our founding in 2017, Herophilus’s vision has been to leverage the parallel revolutions in human complex in vitro brain models, scaled l...

September 12, 2023 | Tuesday | News
HUTCHMED Completes Patient Enrollment for Tazemetostat Study in Chinese Follicular Lymphoma

The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...

September 12, 2023 | Tuesday | News
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China

Second commercialized product strengthens Clover’s leading respiratory vaccine franchise and financial profile--   Clover Biopharmaceutica...

September 12, 2023 | Tuesday | News
MoleculeAI's Quest: Revolutionizing Drug Discovery with Artificial Intelligence

In a rapidly evolving world where scientific breakthroughs are essential for the betterment of healthcare, MoleculeAI stands at the forefront, pioneering t...

September 11, 2023 | Monday | Interaction
Gilead's Phase 2 Study Shows Promise for Trodelvy and KEYTRUDA in First-Line Lung Cancer

– Results Show Encouraging Activity of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC Across all PD-L1 Subgroups and Histologies Studie...

September 11, 2023 | Monday | News
Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices

Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”)  announced a change of the Company’s name to Elutia Inc. The rebranding reflects the ...

September 07, 2023 | Thursday | News
Stallergenes Greer & Nestlé Partner for Palforzia® Peanut Allergy Treatment

Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among childre...

September 05, 2023 | Tuesday | News
ENHERTU® Earns Dual Breakthrough Therapy Designations for HER2-Expressing Cancers in the U.S

Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colo...

September 04, 2023 | Monday | News
Twist Bioscience and Ono Pharmaceutical Collaborate on Autoimmune Antibodies

“Ono has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opd...

September 01, 2023 | Friday | News
Rapid Medical™ Gains Approval in China for the World’s Only Adjustable Thrombectomy Device

Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval for its TIGERTRIEVER revascularization device. With...

September 01, 2023 | Friday | News
23andMe Granted New FDA Clearance to Report Additional BRCA Variants

510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prosta...

September 01, 2023 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close